- Trial phase
- Phase 1
- Time to market
- Years away, if successful. The drug is in Phase 1 safety testing with no disclosed completion timeline. Typical obesity drug development from Phase 1 to FDA approval takes 5-8 years.
- Why 2/10
- No hard, dated catalyst is scheduled for NBIP-1968 in the next ~12 months. The Phase 1 first-in-human study began in August 2026 with no disclosed completion date or data-readout timeline. As an early-stage asset at a diversified company with multiple approved products, even a data event would have limited stock impact.
NBIP-1968 is too early-stage (Phase 1, initiated August 2026) to drive a near-term share-price move for NBIX. Watch for Phase 1 safety/tolerability data readouts, but no specific date has been disclosed. The more relevant catalysts for NBIX in the next 12 months are commercial execution of its approved products (INGREZZA, CRENESSITY, VYKAT XR) and any pipeline updates from its more advanced neurology/psychiatry programs.
Price Chart
Executive Summary
NBIP-1968 is Neurocrine Biosciences' investigational GLP-1/GIP/glucagon receptor triple agonist for obesity, currently in a Phase 1 first-in-human study that began in August 2026. It is designed as a once-weekly injection and intended for fixed-dose combination with Neurocrine's other Phase 1 asset NBIP-2118 (a CRF2 receptor agonist aimed at muscle preservation). The drug enters a highly competitive obesity market where Eli Lilly's retatrutide (same triple-agonist mechanism) is already in Phase 3 with strong weight-loss data. Neurocrine is a well-capitalized, diversified biotech with approximately $1.1B in quarterly revenue from three approved products (INGREZZA, CRENESSITY, VYKAT XR), making NBIP-1968 a small, early-stage pipeline component with no near-term binary catalyst for the stock.
How It Works
NBIP-1968 is a triple agonist, meaning it activates three different hormone receptors at once: GLP-1, GIP, and glucagon. GLP-1 and GIP are natural hormones that help control blood sugar and reduce appetite (similar to how popular weight-loss drugs like Wegovy/Ozempic work). Adding glucagon receptor activation is intended to increase energy burning. The drug is designed as a once-weekly injection and is meant to be combined with another Neurocrine drug (NBIP-2118) that targets a different pathway to preserve muscle mass during weight loss.
Trial Status
A Phase 1 first-in-human study was initiated on August 7, 2026, evaluating single ascending doses of NBIP-1968 for safety and tolerability in adults across BMI categories including overweight and obese. No data readout date has been disclosed.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 safety/tolerability data readout (date not yet disclosed)
- Potential progression to multiple-ascending-dose portion of Phase 1
- Any future combination study with NBIP-2118
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NEUROCRINE BIOSCIENCES INC 8-K NBIX ·Originating report